ClinicalTrials.gg
RecruitingNCT07491523Updated Mar 24, 2026

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

An observational study in SSc-Systemic Sclerosis, sponsored by University of Patras. Recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by University of Patras · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Scleroderma, Systemic with a site in Greece — 4 open to participants now, 5 under way, 3 of them phase 3. Scleroderma, Systemic · Greece.

Started
2025
the only one that year
Observational
2 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
University of Patras

Among the 12 studies in Scleroderma, Systemic with a site in Greece, this one is the only one that started in 2025, is one of 2 observational ones, and was the 10th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

4 of the 12 studies in Scleroderma, Systemic with a site in Greece are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Scleroderma, Systemic with a site in Greece, or all of them as a file.
02

Study summary

Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment

Read the detailed description

Systemic sclerosis (scleroderma) is a rare systemic autoimmune disease. It primarily affects the skin, but it can also involve other vital organs and systems, and is characterized by fibrosis, vascular abnormalities, and the production of autoantibodies. Its main pathological feature is the excessive production and deposition of collagen in the skin and other organs.

Mortality in scleroderma varies depending on the type and severity of the disease, particularly on whether vital organs are involved. Patients with limited cutaneous scleroderma generally have a better prognosis and life expectancy, whereas those with diffuse scleroderma face a higher risk of death from disease-related complications, mainly due to lung involvement.

Pulmonary involvement in scleroderma is common, either affecting the pulmonary blood vessels (pulmonary hypertension) or the supporting structure (interstitium) of the lungs, leading to interstitial fibrosis.

Objective:

The aim of the study is to compare patients receiving only dual immunosuppressive therapy (control group) with patients receiving dual immunosuppressive therapy combined with antifibrotic treatment (e.g., nintedanib).

Methods:

This will be a retrospective study including patients with scleroderma and diffuse pulmonary fibrosis who are followed at the Rheumatology Department of the University General Hospital of Patras and are receiving the two proposed treatment regimens. Because fibrosis and its progression are slow processes, we propose a comparative analysis of outcomes in both groups at 2 years from treatment initiation.

Inclusion criteria:

Presence of pulmonary fibrosis (documented by chest HRCT), regardless of whether pulmonary function tests show a restrictive pattern or not.

Availability of pulmonary function tests for each patient at the following time points:

0 months (baseline) 6 months 12 months Patients (controls) should be receiving either dual therapy (MMF + RTX) or triple therapy (MMF + RTX + nintedanib).

Analysis:

Statistical analysis will be performed using the unpaired two-tailed Student's t-test.

Expected results / originality / contribution to science:

To date, no similar study exists in the international literature. Since interstitial lung disease is the leading cause of death in patients with scleroderma, the results of this study may contribute to improved management. We hypothesize that the combination of dual immunosuppressive therapy and antifibrotic treatment will be superior to dual immunosuppressive therapy alone.

03

Conditions studied

  • SSc-Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with ssc-ild

Eligibility criteria

Inclusion Criteria:ild-ssc with double

-

Exclusion Criteria:

  • ssc without ild
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient with ssc-ild with a double immunosuppression treatment and with anti fibrotic

    Comparison of the two groups

    Drug: Antifibrotic drugs (nidanib or pirfenidone) · Drug: MMF Immunosuppression

  • Patient with ssc-ild with a double immunosuppression treatment only

    Patients with rituximab and mmf

    Drug: MMF Immunosuppression

Interventions

  • DrugAntifibrotic drugs (nidanib or pirfenidone)

    Ssc - ild

  • DrugRituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib

    Also known as: RITUXIMAB

06

What researchers measure

Primary outcomes

  1. pulmonary function test

    For outcome number 1: FVC as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value at each prespecified time point. For outcome number 2: FEV1 as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value obtained at each prespecified time point. For outcome number 3: FEV1/FVC (ratio) compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed between baseline and each subsequent value obtained at each prespecified time point. For outcome number 4: TLCO (corrected for Ht) as a percentage compared to normal values (for age, sex, weight) at: Baseline and at 3, 6 and 12 months of treatment. Comparisons will be performed as described above.

    Time frame: From enrollment till the end of study -1 years later

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.

Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's planned 13 months is below that.

Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 24, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Mar 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07491523
Lead sponsor
University of Patras
Responsible party
Liossis Stamatis Nick (Professor, University of Patras) — Principal investigator
First posted
Mar 24, 2026
Start date
Jun 1, 2025
Primary completion
Jul 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Stamatis Nick Liossis C Professor, MD, PhD
Contact
snliossis@med.upatras.gr
+306977066105

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion